.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
MENDS2 was a large randomised trial comparing dexmedetomidine with propofol for sedation in mechanically ventilated adults with sepsis. The study tackled a clinically important question: could the choice of sedative influence outcomes beyond simply keeping the patient comfortable and synchronised with the ventilator? The trial found no significant difference in the primary outcome of ventilator-free days and alive at 90 days between the two sedative strategies. The result is important because dexmedetomidine is often attractive when clinicians want lighter, more interactive sedation or less respiratory depression, but pharmacological preference should not be confused with proven mortality benefit. The practical message is to select sedation according to the patient's clinical needs, the desired depth of sedation, haemodynamic profile, delirium risk and the broader ICU liberation plan. Routine sedation should be as light as safely possible, with regular reassessment and coordination with spontaneous awakening and breathing trials. This fits CritiCARE 2026's dedicated discussion of sedation, analgesia, neuromuscular blockade, delirium and ventilator liberation. The trial reinforces a core principle of modern ICU practice: sedatives are tools within a care strategy, not endpoints in themselves.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
MENDS2 was a large randomised trial comparing dexmedetomidine with propofol for sedation in mechanically ventilated adults with sepsis. The study tackled a clinically important question: could the choice of sedative influence outcomes beyond simply keeping the patient comfortable and synchronised with the ventilator? The trial found no significant difference in the primary outcome of ventilator-free days and alive at 90 days between the two sedative strategies. The result is important because dexmedetomidine is often attractive when clinicians want lighter, more interactive sedation or less respiratory depression, but pharmacological preference should not be confused with proven mortality benefit. The practical message is to select sedation according to the patient's clinical needs, the desired depth of sedation, haemodynamic profile, delirium risk and the broader ICU liberation plan. Routine sedation should be as light as safely possible, with regular reassessment and coordination with spontaneous awakening and breathing trials. This fits CritiCARE 2026's dedicated discussion of sedation, analgesia, neuromuscular blockade, delirium and ventilator liberation. The trial reinforces a core principle of modern ICU practice: sedatives are tools within a care strategy, not endpoints in themselves.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
